The high level of commercial success experienced by the key companies in the oncology market makes it extremely attractive to drug developers. However, the shift toward a more personalized approach means fewer drugs will achieve blockbuster status. The top 20 looks set to fragment as more clinically and commercially attractive targeted therapies enter the market.
Features and benefits
Highlights
Targeted therapies make up half of the top 20 in 2010 with Roche’s monoclonal antibody franchise maintaining the top three positions. A potential to demonstrate improved clinical efficacy with reduced off-target toxicity, combined with an ability to demand higher prices, makes this drug class clinically and commercially attractive.
The majority of the six cytotoxic brands in the top 20 have now come off patent. The blockbuster sales of these brands will attract generic drug developers which will significantly decrease seven major market sales. As developers turn their attention toward new targeted therapies the number of new cytotoxics entering the market has decreased.
Four antihormonal brands made the top 20, with Lupron maintaining its leading position in this class. These drugs have demonstrated high clinical efficacy, enabling them to establish themselves in breast cancer and prostate cancer. However, the commercial potential of this class has been limited by the low potential for indication expansion.
Comprehensive Table of Contents, Request a Sample and more for the report @ http://www.reportsnreports.com/reports/144203-product-profiles-top-20-cancer-therapy-brands.html
